Tlr agonists for reducing activation-induced pd-1 expression on t cells and methods of use
AssigneeWisconsin Alumni Research Foundation
InventorsDouglas G. McNeel, Christopher D. Zahm
Life of this patent
Estimating the term…
Abstract
The present invention is directed toward methods of increasing the immune response to an antigen using TLR1/2 agonist and/or TLR7 agonist in combination with a T cell activating treatment, for example, a vaccine. In some aspects, the present invention provides methods of enhancing an anti-tumor response comprising administering at least one TLR1/2 agonist and/or at least one TLR7 agonist in combination with an immunotherapeutic agent.
Claims21
A method of eliciting an anti-tumor response in a subject in need thereof, the method comprising administering at least one TLR1/2 agonist or TLR7 agonist and an anti-tumor vaccine to the subject in an effective amount to elicit an anti-tumor response in said subject.
A method of increasing the immune response to an antigen, the method comprising administering at least one TLR1/2 agonist or TLR7 agonist and at least one vaccine directed to said antigen in a subject, wherein the immune response to said antigen is increased relative to a subject treated with the vaccine alone.
-19. (canceled)
A composition for eliciting an anti-tumor response, the composition comprising at least one TLR1/2 agonist and/or at least one TLR7 agonist and at least one immunotherapeutic agent.
Dependencies are inferred from the claim text.